Gecioni Loch-Neckel

Gecioni Loch-Neckel

Auto-generated profile, based on publicly available information

Gecioni Loch-Neckel

Universidade Federal de Santa Catarina, Brasil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2015 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
LMLetícia Mazzarino
Letícia Mazzarino
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
LBLorena dos Santos Bubniak
Lorena dos Santos Bubniak
FOFabiana Ourique
Fabiana Ourique
Issei OtsukaIssei Otsuka
Issei Otsuka
RBRedouane Borsali
Redouane Borsali
Xyloglucan-block-polycaprolactone (XGO-PCL) copolymer nanoparticles have been proposed as nanocarriers for drug delivery. However, the possible harmful effects of exposure to nanoparticles still remain a concern. Therefore, the aim of this study is to evaluate the potential toxicity of XGO-PCL nanoparticles using in vitro and in vivo assays. Cytotoxicity and genotoxicity studies were conducted on MRC-5 human fetal lung fibroblast cells upon exposure to XGO-PCL nanoparticles. No significant reduction in the cell viability and no DNA damage were observed at the different concentrations tested. Erythrocyte toxicity was assessed by the incubation of nanoparticles with human blood. XGO-PCL nanoparticles induced a hemolytic ratio of less than 1%, indicating good blood compatibility. Finally, the subacute toxicity of XGO-PCL nanoparticles (10 mg/kg/day) was evaluated in BALB/c mice when administered orally or intraperitoneally for 14 days. Results of the in vivo toxicity study showed no clinical signs of toxicity, mortality, weight loss, or hematological and biochemical alterations after treatment with nanoparticles. Also, microscopic analysis of the major organs revealed no histopathological abnormalities, corroborating the previous results. Thus, it can be concluded that XGO-PCL nanoparticles induced no effect indicative of toxicity, indicating their potential use as drug delivery systems.

1 January 2015 in Journal of Nanoscience and Nanotechnology
Verified
Journal Article
Closed access
LMLetícia Mazzarino
Letícia Mazzarino
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
LBLorena Dos Santos Bubniak
Lorena Dos Santos Bubniak
SMSuelen Mazzucco
Suelen Mazzucco
MSMaria Cláudia Santos-Silva
Maria Cláudia Santos-Silva
ELElenara Lemos-Senna
Elenara Lemos-Senna
Mucoadhesive nanoparticles loaded with curcumin were developed as a new approach to deliver curcumin for the local treatment of oral cancer. PCL nanoparticles coated with chitosan displaying different molar masses were prepared by using the nanoprecipitation technique. The mucoadhesive properties of nanoparticle suspensions were demonstrated by their strong ability to interact with the glycoprotein mucin through electrostatic interactions. Similar permeation profiles of curcumin loaded in uncoated and chitosan-coated nanoparticles across porcine esophageal mucosa were verified. Curcumin concentrations retained in the mucosa suggest the possibility of a local effect of the drug. In vitro studies demonstrated that free curcumin and curcumin loaded into nanoparticles coated with chitosan caused significant reduction of SCC-9 human oral cancer cell viability in a concentration and time-dependent manner. However, no significant cell death was observed after 24 h of treatment with unloaded nanoparticles coated with chitosan. In addition, curcumin-loaded nanoparticles showed reduced cytotoxicity, when compared with the free drug. Therefore, chitosancoated PCL nanoparticles may be considered a promising strategy to deliver curcumin directly into the oral cavity for the treatment of oral cancer.

1 July 2011 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
PMPéricles Arruda Mitozo
Péricles Arruda Mitozo
LSLuiz Felipe de Souza
Luiz Felipe de Souza
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
SFSamira Flesch
Samira Flesch
AMAngelica Francesca Maris
Angelica Francesca Maris
ADAlcir Dafre
Alcir Dafre

Verified
Journal Article
Open access
PDF file
AVAna Rita Vaz
Ana Rita Vaz
DVDaniela Vizinha
Daniela Vizinha
HMHermes Morais
Hermes Morais
ACAna Rita Colaço
Ana Rita Colaço
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
Dora BritesDora Brites
Dora Brites
MiRNA(miR)-124 is an important regulator of neurogenesis, but its upregulation in SOD1G93A motor neurons (mSOD1 MNs) was shown to associate with neurodegeneration and microglia activation. We used pre-miR-124 in wild-type (WT) MNs and anti-miR-124 in mSOD1 MNs to characterize the miR-124 pathological role. miR-124 overexpression in WT MNs produced a miRNA profile like that of mSOD1 MNs (high miR-125b; low miR-146a and miR-21), and similarly led to early apoptosis. Alterations in mSOD1 MNs were abrogated with anti-miR-124 and changes in their miRNAs mostly recapitulated by their secretome. Normalization of miR-124 levels in mSOD1 MNs prevented the dysregulation of neurite network, mitochondria dynamics, axonal transport, and synaptic signaling. Same alterations were observed in WT MNs after pre-miR-124 transfection. Secretome from mSOD1 MNs triggered spinal microglia activation, which was unno-ticed with that from anti-miR-124-modulated cells. Secretome from such modulated MNs, when added to SC organotypic cultures from mSOD1 mice in the early symptomatic stage, also coun-teracted the pathology associated to GFAP decrease, PSD-95 and CX3CL1-CX3CR1 signaling im-pairment, neuro-immune homeostatic imbalance, and enhanced miR-124 expression levels. Data suggest that miR-124 is implicated in MN degeneration and paracrine-mediated pathogenicity. We propose miR-124 as a new therapeutic target and a promising ALS biomarker in patient sub-populations.

1 October 2015 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
LSLorena Santos-Bubniak
Lorena Santos-Bubniak
LMLetícia Mazzarino
Letícia Mazzarino
AJAmanda V. Jacques
Amanda V. Jacques
BMBárbara Moccelin
Bárbara Moccelin
ELElenara Lemos-Senna
Elenara Lemos-Senna

1 October 2009 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
PDF file
GLGecioni Loch-Neckel
Gecioni Loch-Neckel
GSGiane Seemann
Giane Seemann
HEHelena Berton Eidt
Helena Berton Eidt
MRMichelli Moroni Rabuske
Michelli Moroni Rabuske
MCMaria Aparecida Crepaldi
Maria Aparecida Crepaldi
O Programa Saúde da Família (PSF) surge como uma nova estratégia de atenção à saúde e de reorientação do modelo de assistência. Partindo desses pressupostos, o presente artigo tem como objetivo refletir sobre a relação entre integralidade na atenção básica e a composição das equipes de saúde da família, na perspectiva dos integrantes da equipe mínima do PSF, caracterizando as possibilidades de atuação e contribuições de outros profissionais de saúde no PSF. Participaram da pesquisa profissionais com curso superior, membros de equipes de PSF de um município no sul do Brasil. A qualidade da experiência profissional ou pessoal acerca da atuação desses profissionais contribuiu para o conhecimento sobre suas possibilidades de intervenção. A investigação permitiu também analisar como a estratégia de saúde da família tem atingido os integrantes que constituem as equipes mínimas no contexto local. Além disso, evidenciou de que maneira a integralidade e a interdisciplinaridade têm sido entendidas pelos que compõem tais equipes, e as relações entre a composição das equipes e as (im)possibilidades de concretizá-la.